12 completed, 12 recruiting, 9 unknown, 7 active not recruiting. 48 Phase 2, 9 Phase 3, 2 Phase 1.
Follow Triptorelin Pamoate: new trials by email Literature Review of Triptorelin Pamoate trials Research Report on Triptorelin Pamoate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| COMPASS - COpenhagen MenoPAuSe Study Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2) - Menopausal Osteoporosis, Bone Markers | Phase 2 | Recruiting | Martin Blomberg Jensen | 192 | 2025-10-02 | 2026-03-02 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 231 | 2024-01-23 | 2026-02-24 |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers Darolutamide, Darolutamide matched placebo, Radiotherapy - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Cancer Research Antwerp | 493 | 2023-12-13 | 2026-03-19 |
| Dose Escalation For INtraprostatic LEsions Prostate SBRT with Focal Boost, Triptorelin Injection - Prostatic Neoplasms | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 54 | 2023-11-23 | 2024-01-05 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer Elacestrant, Triptorelin, Tamoxifen 20 mg - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | SOLTI Breast Cancer Research Group | 96 | 2023-02-03 | 2026-04-24 |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Olaparib, LHRH agonist - Prostate Cancer, BRCA1 Mutation | Phase 2 | Active not recruiting | Rana McKay, MD | 32 | 2023-02-01 | 2026-07-10 |
| DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation Triptorelin 3.75 MG Injection, Transvaginal oocyte retrieval, Triptorelin Injection - Breast Cancer Female | Phase 1 / Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 30 | 2022-11-01 | 2023-05-18 |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer | Phase 2 | Unknown | Fudan University | 160 | 2022-04-01 | 2022-03-16 |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel - Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2022-01-25 | 2025-12-04 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
| Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis GnRH agonist - Endometriosis, Adenomyosis | Phase 2 / Phase 3 | Recruiting | Hopital Foch | 180 | 2021-03-18 | 2026-01-16 |
| Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer Decapeptyl - Prostate Cancer | Phase 2 | Recruiting | Regina Elena Cancer Institute | 146 | 2021-02-02 | 2022-09-28 |
Showing 20 of 48. Sign in to see all of them.
Prostatic Neoplasms (23) · Breast Neoplasms (8) · Infertility (4) · Infertility, Female (3) · Endometriosis (2) · Lymphoma (2) · Neoplasms (2) · Adenocarcinoma (1) · Adenomyosis (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Drug-Related Side Effects and Adverse Reactions (1) · Endometritis (1) · Helping Behavior (1) · Leiomyoma (1) · Lupus Erythematosus, Systemic (1)
Ipsen (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Universitair Ziekenhuis Brussel (3) · Cancer Research Antwerp (2) · ETOP IBCSG Partners Foundation (2) · Fudan University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Aragon Pharmaceuticals, Inc. (1) · Aristotle University Of Thessaloniki (1) · Armando Santoro, MD (1) · Assistance Publique - Hôpitaux de Paris (1) · Baptist Health South Florida (1) · Benha University (1) · Children's Hospital Medical Center, Cincinnati (1) · Erasme University Hospital (1)
United States (16) · Belgium (8) · Italy (8) · France (5) · Canada (3) · China (3) · Germany (3) · Spain (3) · Greece (2) · Netherlands (2) · Austria (1) · Brazil (1) · Denmark (1) · Egypt (1) · Hungary (1)
Jingsong Zhang, MD, PhD (2) · Samuel Denmeade, MD (2) · Abhishek Solanki, MD MS (1) · Armando Santoro, MD (1) · Arthur Hung (1) · Dingwei Ye, Doctoral (1) · Edwin Posadas, MD (1) · Efstratios Kolibianakis, MD, MSc, PhD (1) · Elisabetta Munzone, MD (1) · Elizabeth Kessler, MD (1) · Gert De Meerleer, MD, PhD (1) · Hannah Linden (1)
PMID 23129737, PMID 25676588, PMID 25904960, PMID 30589600, PMID 32356465, PMID 32666822, PMID 34667023, PMID 35780048, PMID 36710203, PMID 37435500, PMID 38421243, PMID 40907514, PMID 40998687, PMID 42117295
2005 (1), 2015 (1), 2016 (1), 2025 (1), I01CX002277 (1), P30CA076292 (1), P50CA272391 (1), R01CA286127 (1), R01CA300454 (1)